Crucial areas of the economic analysis of public cancer care

Introduction. The economic aspects of providing cancer care to the public attract increasing attention of scientists, economists, physicians and other healthcare professionals. Currently, the healthcare economics of oncological institutions is defined as part of the national economy that implements cancer care programs and provide a wide range of medical and pharmaceutical services to the public.

Aim. The study was conducted as part of the program for improvement of financial spending in order to facilitate cancer care for Moscow residents. The aim of this study was to identify the crucial areas of the cost analysis and thus improve the public health service.

Materials and methods. We used the methodology of targeted and consistent search of the literature. The data search and analysis was carried out using the US National Medical Library (PubMed database), National Electronic Library (e-LIBRARY, Russia), and other Internet resources. Whenever possible, articles on the most common and socially significant types of cancer (breast, colon, prostate, lung etc.) were selected. In addition, we focused on significant studies conducted either on the national or international level.

Results and discussion. In principle, the structure of total costs is determined by the health policy regarding the cancer care system. Six main areas of oncological care that require careful economic analysis have been identified: those are prevention, oncoscreening, diagnosis, treatment, rehabilitation, and palliative care. In order to implement the economic goals of the healthcare system, the cost of cancer treatment should be discussed. The relevant programs are expected to be based on 1) prevalence and incidence; 2) impact on health; 3) results of the integrative methodological approach to cancer treatment; 4) implementation of comprehensive measures of medical and social assistance; 5) use of financial mechanisms and their impact on economic indicators.

Conclusion. The set of measures related to the direct costs as identified in this study include the development, planning and provision of cancer care. These specific features of the direct cost analysis are important for organizing medical care in oncological institutions.

1. Vyalkov A.I., Kucherenko V.Z., Raizberg B.A. et al. Management and health economics. 3rd ed., Ext. / Ed. A.I. Vyalkova. Moscow. 2013; 664 s.

2. Cancer: Key Figures and Facts. [Electronic resource] URL: https://www.who.int/cancer/about/facts/ru/. Accessed: 14.08.2019.

3. Kaprin A.D., Starinskii V.V., Petrovа G.V. Malignant neoplasms in Russia in 2017 (morbidity and mortality). Moscow. 2018; 250 s.

4. Kaprin A.D., Starinskii V.V., Petrovа G.V. The status of cancer care for the population of Russia in 2017. Moscow. 2018; 236 s.

5. Latest global cancer data: Cancer burden rises to 18.1 million new cases and 9.6 million cancer deaths in 2018. International Agency for Research on Cancer (WHO) 2018.

6. Latest world cancer statistics. Global cancer burden rises to 14.1 million new cases in 2012: Marked increase in breast cancers must be addressed. World Health Organization; 2012.

7. Bray F., Soerjomataram I. The Changing Global Burden of Cancer: Transitions in Human Development and Implications for Cancer Prevention and Control. In: Gelband H., Jha P., Sankaranarayanan R., Horton S., editors. Cancer: Disease Control Priorities, Third Edition (Volume 3). Washington (DC) 2015.

8. Thun M.J., DeLancey J.O., Center M.M., Jemal A., Ward E.M. The global burden of cancer: priorities for prevention. Carcinogenesis. 2010; 31 (1): 100-10. https://doi.org/10.1093/carcin/bgp263.

9. Cancer. Key facts. World Health Organization. 2018. [Electronic resource] URL: https://www.who.int/news-room/fact-sheets/detail/cancer. Accessed: 01.09.2019.

10. Lyman G.H. Economics of cancer care. J Oncol Pract. 2007; 3 (3): 113-4. https://doi.org/10.1200/JOP.0731501.

11. Ignat’eva V.I., Derkach E.V., Omel’yanovskii V.V., Avksent’eva M.V. The Social and Economic Burden of Cancer in the Russian Federation. Meditsinskie tekhnologii. Otsenka i vybor (in Russ.). 2013; 4 (14): 73-80.

12. Jönsson B. Cost of Cancer: Healthcare Expenditures and Economic Impact. Regulatory and Economic Aspects in Oncology. Springer, Cham, 2019; 7-23.

13. Greenberg D., Earle C., Fang C.H., Eldar-Lissai A., Neumann P.J. When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncology. J Natl Cancer Inst. 2010; 102 (2): 82-8. https://doi.org/10.1093/jnci/djp472.

14. Avksentyeva M.V., Gorkavenko F.V., Nikitina F.V., Savilova A.G., Gerasimova K.V., Musina N.Z., Omelyanovskii V.V. Estimation of Socioeconomic Burden of Lung Cancer in the Russian Federation. Meditsinskie tekhnologii. Otsenka i vybor (in Russ.). 2018. № 4 (34). С. 63-75.

15. Services USDoHSaH. Fact Book. National Cancer Institute. 2001. [Electronic resource] URL: https://www.cancer.gov/about-nci/budget/fact-book/archive/2001-fact-book.pdf. Accessed: 01.09.2019.

16. Johnson E.F., Dominici M., Griswold SLZ. Disease cases and their medical costs attributable to smoking: an analysis of the national medical expenditure survey. J Econom. 2003; 112 (1): 135-51.

17. Bosanquet N., Karol S. The economics of cancer care: Cambridge University Press; 2006.

18. Goldie S.J., Daniels N. Model-based analyses to compare health and economic outcomes of cancer control: inclusion of disparities. J Natl Cancer Inst. 2011; 103 (18): 1373-86. https://doi.org/10.1093/jnci/djr303.

19. Wong W.B., Wu N., Yang E., Davies J., Chae Y.K. Real-World Clinical and Economic Outcomes and the Role of Bevacizumab in Patients With Non-Small-Cell Lung Cancer With Liver Metastases. J Oncol Pract. 2019; 15 (10): e878-e87. https://doi.org/10.1200/JOP.19.00166.

20. Lee J.A., Kim S.Y., Park K., Park E.C., Park J.H. Analysis of Hospital Volume and Factors Influencing Economic Outcomes in Cancer Surgery: Results from a Population-based Study in Korea. Osong Pub lic Health Res Perspect. 2017; 8 (1): 34-46. https://doi.org/10.24171/j.phrp.2017.8.1.05.

21. Fryback D.G., Craig B.M. Measuring economic outcomes of cancer. J Natl Cancer Inst Monogr. 2004; 33: 134-41.

22. Homan S.G., Yun S., Bouras A., Schmaltz C., Gwanfogbe P., Lucht J. Breast Cancer Population Screening Program Results in Early Detection and Reduced Treatment and Health Care Costs for Medicaid. J Public Health Manag Pract. 2019. https://doi.org/10.1097/PHH.0000000000001041.

23. Kim E.Y., Shim Y.S., Kim Y.S., Lee S.P., Ko K.D., Choi W.J. Adherence to general medical checkup and cancer screening guidelines according to self-reported smoking status: Korea National Health and Nutrition Examination Survey (KNHANES) 2010-2012. PLoS One. 2019; 14 (10): e0224224. https://doi.org/10.1371/journal.pone.0224224.

24. Stewart B.W., Kleihues P. World cancer report: IARCPress; 2003.

25. Giovagnoli M.R., Bonifacino A., Neglia C., Benvenuto M., Sambati FV., Giolli L., et al. Diagnostic and therapeutic path of breast cancer: effectiveness, appropriateness, and costs – results from the DOCMa study. Clin Interv Aging. 2015; 10: 741-9. https://doi.org/10.2147/CIA.S75486.

26. Bosanquet N., Salisbury C. Providing a Palliative Care Service Towards an Evidence Base. OUP, UK. 1999.

27. Lafuma A., Cotte F.E., Le Tourneau C., Emery C., Gaudin A.F., Torreton E., et al. Economic burden of chemotherapy-treated recurrent and/or metastatic squamous cell carcinoma of the head and neck in France: real-world data from the permanent sample of national health insurance beneficiaries. J Med Econ. 2019; 22 (7): 698-705. https://doi.org/10.1080/13696998.2019.1594837.

28. Rashid N., Koh H.A., Baca H.C., Lin K.J., Malecha S.E., Masaquel A. Economic burden related to chemotherapy-related adverse events in patients with metastatic breast cancer in an integrated health care system. Breast Cancer (Dove Med Press). 2016; 8: 173-81. https://doi.org/10.2147/BCTT.S105618.

29. Peng Y., Ma F., Tan C., Wan X., Yi L., Peng L., et al. Model-Based Economic Evaluation of Ceritinib and Platinum-Based Chemotherapy as First-Line Treatments for Advanced Non-Small Cell Lung Cancer in China. Adv Ther. 2019; https://doi.org/10.1007/s12325-019-01103-4.

30. Zelenova O.V., Bolotina L.V., Rusakov I.G., Ivakhnenko O.I., Krysanov I.S. An economic comparison of different treatments for generalized kidney cancer. Direct medical expenses in an oncology hospital. Kreativnaya khirurgiya i onkologiya (in Russ). 2011; 4: 73-8.

31. Heitland W., Schadlich P.K., Chen X., Remy V., Moro L. Annual cost of hospitalization, inpatient rehabilitation and sick leave of anal cancer in Germany. J Med Econ. 2013; 16 (3): 364-71. https://doi.org/10.3111/13696998.2012.759582.

32. Round J., Leurent B., Jones L. A cost-utility analysis of a rehabilitation service for people living with and beyond cancer. BMC Health Serv Res. 2014; 14: 558. https://doi.org/10.1186/s12913-014-0558-5.

33. Mewes J.C., Steuten L.M., Ijzerman M.J., van Harten WH. Effectiveness of multidimensional cancer survivor rehabilitation and cost-effectiveness of cancer rehabilitation in general: a systematic review. Oncologist. 2012; 17 (12): 1581-93. https://doi.org/10.1634/theoncologist.2012-0151.

34. Gordon L.G., Scuffham P., Battistutta D., Graves N., Tweeddale M., Newman B. A cost-effectiveness analysis of two rehabilitation support services for women with breast cancer. Breast Cancer Res Treat. 2005; 94 (2): 123-33. https://doi.org/10.1007/s10549-005-5828-9.

35. Enguidanos S.M., Cherin D., Brumley R. Home-based palliative care study: site of death, and costs of medical care for patients with congestive heart failure, chronic obstructive pulmonary disease, and cancer. J Soc Work End Life Palliat Care. 2005; 1 (3): 37-56. https://doi.org/10.1300/J457v01n03_04.

36. Guest J.F., Ruiz F.J., Greener M.J., Trotman I.F. Palliative care treatment patterns and associated costs of healthcare resource use for specific advanced cancer patients in the UK. Eur J Cancer Care (Engl). 2006; 15 (1): 65-73. https://doi.org/10.1111/j.1365-2354.2005.00623.x.

37. Witteveen P.O., van Groenestijn M.A., Blijham G.H., Schrijvers A.J. Use of resources and costs of palliative care with parenteral fluids and analgesics in the home setting for patients with end-stage cancer. Ann Oncol. 1999; 10 (2): 161-5. https://doi.org/10.1023/a:1008364401890.

38. Bates M.J., Namisango E., Tomeny E., Muula A., Squire S.B., Niessen L. Palliative care within universal health coverage: the Malawi Patient-and-Carer Cancer Cost Survey. BMJ Support Palliat Care. 2019; https://doi.org/10.1136/bmjspcare-2019-001945.

39. Saygili M., Celik Y. An evaluation of the cost-effectiveness of the different palliative care models available to cancer patients in Turkey. Eur J Cancer Care (Engl). 2019; 28 (5): e13110. https://doi.org/10.1111/ecc.13110.

40. Rozman L.M., Campolina A.G., Lopez R.M., Chiba T., De Soarez P.C. Palliative cancer care: costs in a Brazilian quaternary hospital. BMJ Support Palliat Care. 2019. https://doi.org/10.1136/bmjspcare-2019-001809.

41. Andreev D.A., Bashlakova E.E., Khachanova N.V., Davydovskaia M.V. Cystic Fibrosis Patient Registries: Domestic and Foreign Experience. Pediatric pharmacology (In Russ.). 2017; 14 (2): 115-126/ https://doi.org/10.15690/pf.v14i2.1726.

42. Bashlakova E.E., Andreev D.A., Khachanova N.V., Davydovskaya M.V. Registry. Registries. Types of registries. Registries of Hemophilia (review). Vrach i informatsionnye tekhnologii (in Russ). 2018; 1: 33-42.

43. Andreev D.A., Khachanova N.V., Kokushkin K.A., Davydovskaya M.V. Multiple sclerosis registries as a vital element in the transition to the value-based healthcare. Problemy standartizatsii v zdravookhranenii (in Russ). 2018; 3-4: 35-45.